Fundraising Fox
KaliVir Immunotherapeutics
1 known investors
Find your way into KaliVir Immunotherapeutics
Sign up to see every warm intro you have to KaliVir Immunotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the KaliVir Immunotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
KaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
Founders & leadership
ST
Stephen ThorneCo-founder & Chief Scientific OfficerStephen Thorne is Co-founder and Chief Scientific Officer of KaliVir Immunotherapeutics, an immuno-oncology company developing oncolytic viral immunotherapies for solid tumors. He brings over 15 years of research and leadership experience in translational development of cancer immunotherapies, including immune cell therapies, oncolytic viral therapies, and gene therapy, along with expertise in immunocompetent mouse models, molecular imaging, and process development for complex biologics.
SG
Schond GreenwayChief Financial OfficerSchond Greenway is Chief Financial Officer of KaliVir Immunotherapeutics, bringing over 25 years of finance experience across investment banking, equity research, and capital markets roles at publicly traded life sciences companies, where he secured substantial growth capital for early-stage firms.
Investors · 1
Funding
SEC filings, press & company announcements$14M disclosed across 1 of 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does KaliVir Immunotherapeutics do?
- KaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
- Who founded KaliVir Immunotherapeutics?
- KaliVir Immunotherapeutics was founded by Stephen Thorne.
- Who are KaliVir Immunotherapeutics's investors?
- KaliVir Immunotherapeutics's investors include Premier Partners.
- How much funding has KaliVir Immunotherapeutics raised?
- KaliVir Immunotherapeutics has disclosed $14M raised across 1 of its 2 known rounds.